CN Stock MarketDetailed Quotes

600223 Lushang Freda Pharmaceutical

Watchlist
  • 7.32
  • -0.14-1.88%
Market Closed Dec 13 15:00 CST
7.44BMarket Cap31.42P/E (TTM)

Lushang Freda Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Lushang Freda Pharmaceutical Q3 2024 Earnings Date

Currency：CNYOct 29, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
--
877.19M
--
-4.82%
EPS
--
0.04
--
--
Analyst Rating
Strong Buy

Dec 13, 2024

Lushang Freda Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 9 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CNY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/FY-- / 4.852B--
--2024/FY-- / 4.221B--
Mar 22, 20242023/FY4.579B / 4.544B--
Mar 31, 20232022/FY12.951B / 12.040B--
--2021/FY12.363B / 15.184B--
DatePeriodRevenue/EstimateEarnings Call
--2025/FY-- / 4.852B--
--2024/FY-- / 4.221B--
Mar 22, 20242023/FY4.579B / 4.544B--
Mar 31, 20232022/FY12.951B / 12.040B--
--2021/FY12.363B / 15.184B--

Unlock Free Earnings Estimates

Lushang Freda Pharmaceutical Earnings Reports

  • Freda: Report of Lushang Freda Pharmaceutical Co., Ltd. for the third quarter of 2024

    Oct 29 00:00

  • Announcement of Lushang Freda Pharmaceutical Co., Ltd. on the main operating data for the third quarter of 2024

    Oct 29 00:00

  • Lushang Freda Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024

    Oct 29 00:00

  • lushang freda pharmaceutical Co., Ltd. Semi-annual Report 2024

    Aug 24 00:00

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 13, 2024

    Strong Buy

    • Strong Buy

      68.75%

    • Buy

      31.25%

    • Hold

      0.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    CN
    Overall
    Symbol
    Price
    % Chg

    No Data

    Investment Theme Tencent Concept
    Tencent Concept
    Intraday-1.09%
    Spin-off Listing Expectations
    Spin-off Listing Expectations
    Intraday-1.77%
    State-owned Enterprise Reform
    State-owned Enterprise Reform
    Intraday-1.79%